Attached files

file filename
EX-99.1 - PRESS RELEASE - NeuBase Therapeutics, Inc.ex99-1.htm

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 19, 2014

 

Ohr Pharmaceutical, Inc.
(Exact name of registrant as specified in its charter)

 

         
Delaware   333-88480   #90-0577933
(State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)
     
800 3rd Avenue, 11th Floor, New York, NY   10022
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (212)-682-8452

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

Item 8.01.  Other Items.

 

On February 19, 2014, a case study from the registrant’s ongoing OHR-003 trial evaluating Squalamine eye drops in proliferative diabetic retinopathy was presented at the Macula Society meeting in Key Largo, Florida. The registrant issued a press release with additional details from the presentation, a copy of which is being furnished as exhibit 99.1 to Form 8-K.

 

Exhibit No   Description
     
99.1   Press Release Dated February 20, 2014

 

 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized..

 

Dated: February 20, 2014 OHR PHARMACEUTICAL, INC.
   
  By:  /s/ Irach Taraporewala,
    Dr. Irach Taraporewala, President and CEO